Research Funding for the National Institutes of Health Ensures Lifesaving Research Continues
The world’s leading breast cancer organization Susan G. Komen® today applauded Congressional leaders for making a vital investment in the health and well-being of Americans by including a $2 billion increase for the National Institutes of Health (NIH) in the FY17 Omnibus Appropriations Bill. This includes funding for the previously passed 21st Century Cures Act, specifically to support the Beau Biden Cancer Moonshot Initiative, a priority for Komen.
The bill, which passed this week in both the House and the Senate and was signed by President Trump on Friday, also provides continued funding for the Department of Defense’s Breast Cancer Research Program (BCRP).
“We are extremely pleased to see research funding for NIH increased in this legislation – particularly while so many questions remain about the future of health care in this country,” said Komen Interim President and CEO Ellen Willmott. “This funding will help ensure clinical advances for the treatment, prevention and screening of breast cancer continue.”
The bill also continues funding for the National Breast and Cervical Cancer Early Detection Program (NBCCEDP) – a vital safety net program for underserved women. NBCCEDP provides screening and diagnostic services as well as education, outreach, patient navigation, care coordination and quality assurance to increase breast cancer screening rates and reach underserved populations.
“We applaud this bipartisan effort, and hope to see continued collaboration on behalf of the millions of Americans affected by breast cancer every year who are depending on their representatives to prioritize their health,” Willmott said.